Clinical characteristics of patients with aplastic anemia
| . | Age (y) . | HLA . | PNH . | Therapy . | PB counts at presentation . | PB counts at 3 months . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A*02 . | DRB1*15 . | ANC . | ALC . | Hgb . | ARC . | Ptl . | ANC . | ALC . | Hgb . | ARC . | Ptl . | ||||
| 1 | 30 | Y | N | N* | Ctx/CsA | 1 200 | 2 498 | 9.2 | 2 | 19 | 2 048 | 1 305 | 8.6 | 38 | 26 |
| 2 | 46 | N | Y | 1.7% | ATG/CsA | 1 800 | 3 113 | 7.9 | 65 | 15 | 3 400 | 2 899 | 12 | 73 | 69 |
| 3 | 36 | N | Y | 7.6% | ATG/CsA | 560 | 2 200 | 7.7 | 46 | 25 | 886 | 1 733 | 11.8 | 85 | 83 |
| MMF | |||||||||||||||
| 4 | 57 | N | Y | 7.7% | ATG/CsA | 526 | 1 469 | 8 | 32 | 19 | 1 342 | 126 | 10.1 | 80 | 57 |
| MMF | |||||||||||||||
| 5 | 15 | N | N | N | ATG/CsA | 113 | 1 942 | 9.5 | 1 | 14 | 1 480 | 1 085 | 9.2 | 31 | 58 |
| MMF | |||||||||||||||
| 6 | 9 | Y | N | N | ATG/CsA | 403 | 1 541 | 7.8 | 28 | 23 | 627 | 1 299 | 10.5 | 85 | 57 |
| MMF | |||||||||||||||
| 7 | 51 | Y | Y | N | ATG/CsA | 22 | 433 | 9.1 | 4 | 12 | 4 797 | 1 151 | 10.3 | 52 | 93 |
| MMF | |||||||||||||||
| 8 | 48 | Y | N | N | Ctx/CsA | 437 | 3 015 | 10.3 | 10 | 60 | 1 530 | 459 | 8.4 | 58 | 24 |
| 9 | 28 | Y | Y | N | ATG/CsA | 279 | 2 540 | 8.2 | 17 | 9 | 5 768 | 1 694 | 11.9 | 66 | 284 |
| MMF | |||||||||||||||
| 10 | 54 | N | Y | N | ATG/CsA | 21 | 2 006 | 10.2 | 6 | 45 | 297 | 2 544 | 8.8 | 42 | 57 |
| 11 | 47 | N | Y | 15% | ATG/CsA | 287 | 1 900 | 9.1 | 39 | 30 | 1 279 | 1 300 | 7.2 | 73 | 13 |
| MMF | |||||||||||||||
| 12 | 50 | N | Y | 6.5% | ATG/CsA | 160 | 1 364 | 7.7 | 14 | 8 | 954 | 1 200 | 9.4 | 126 | 12 |
| 13 | 38 | Y | N | N | Ctx/CsA | 765 | 682 | 8.2 | 15 | 2 | 1 066 | 391 | 9 | 23 | 30 |
| 14 | 56 | Y | Y | N | G-CSF/SCF | 11 900 | 3 600 | 10.2 | 10 | 11.9 | ND | ND | ND | ND | ND |
| 15 | 35 | N | N | 76% | G-CSF | 906 | 1 567 | 9.7 | 180 | 48 | ND | ND | ND | ND | ND |
| . | Age (y) . | HLA . | PNH . | Therapy . | PB counts at presentation . | PB counts at 3 months . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A*02 . | DRB1*15 . | ANC . | ALC . | Hgb . | ARC . | Ptl . | ANC . | ALC . | Hgb . | ARC . | Ptl . | ||||
| 1 | 30 | Y | N | N* | Ctx/CsA | 1 200 | 2 498 | 9.2 | 2 | 19 | 2 048 | 1 305 | 8.6 | 38 | 26 |
| 2 | 46 | N | Y | 1.7% | ATG/CsA | 1 800 | 3 113 | 7.9 | 65 | 15 | 3 400 | 2 899 | 12 | 73 | 69 |
| 3 | 36 | N | Y | 7.6% | ATG/CsA | 560 | 2 200 | 7.7 | 46 | 25 | 886 | 1 733 | 11.8 | 85 | 83 |
| MMF | |||||||||||||||
| 4 | 57 | N | Y | 7.7% | ATG/CsA | 526 | 1 469 | 8 | 32 | 19 | 1 342 | 126 | 10.1 | 80 | 57 |
| MMF | |||||||||||||||
| 5 | 15 | N | N | N | ATG/CsA | 113 | 1 942 | 9.5 | 1 | 14 | 1 480 | 1 085 | 9.2 | 31 | 58 |
| MMF | |||||||||||||||
| 6 | 9 | Y | N | N | ATG/CsA | 403 | 1 541 | 7.8 | 28 | 23 | 627 | 1 299 | 10.5 | 85 | 57 |
| MMF | |||||||||||||||
| 7 | 51 | Y | Y | N | ATG/CsA | 22 | 433 | 9.1 | 4 | 12 | 4 797 | 1 151 | 10.3 | 52 | 93 |
| MMF | |||||||||||||||
| 8 | 48 | Y | N | N | Ctx/CsA | 437 | 3 015 | 10.3 | 10 | 60 | 1 530 | 459 | 8.4 | 58 | 24 |
| 9 | 28 | Y | Y | N | ATG/CsA | 279 | 2 540 | 8.2 | 17 | 9 | 5 768 | 1 694 | 11.9 | 66 | 284 |
| MMF | |||||||||||||||
| 10 | 54 | N | Y | N | ATG/CsA | 21 | 2 006 | 10.2 | 6 | 45 | 297 | 2 544 | 8.8 | 42 | 57 |
| 11 | 47 | N | Y | 15% | ATG/CsA | 287 | 1 900 | 9.1 | 39 | 30 | 1 279 | 1 300 | 7.2 | 73 | 13 |
| MMF | |||||||||||||||
| 12 | 50 | N | Y | 6.5% | ATG/CsA | 160 | 1 364 | 7.7 | 14 | 8 | 954 | 1 200 | 9.4 | 126 | 12 |
| 13 | 38 | Y | N | N | Ctx/CsA | 765 | 682 | 8.2 | 15 | 2 | 1 066 | 391 | 9 | 23 | 30 |
| 14 | 56 | Y | Y | N | G-CSF/SCF | 11 900 | 3 600 | 10.2 | 10 | 11.9 | ND | ND | ND | ND | ND |
| 15 | 35 | N | N | 76% | G-CSF | 906 | 1 567 | 9.7 | 180 | 48 | ND | ND | ND | ND | ND |
HLA indicates human leukocyte antigen; PNH, paroxysmal nocturnal hemoglobinuria; ANC, absolute neutrophil count (/μL); ARC, absolute reticulocyte (/μL); ALC, absolute lymphocyte count (/μL); Hgb, hemoglobin (g/dL); Ptl, platelets (× K/μL); Y, yes; N, no; Ctx, cyclophosphamide; CsA, cyclosporine; ATG, antithymocyte globulin; MMF, mycophenolate mofetil; G-CSF, granulocyte colony-stimulating factor; SCF, stem cell factor.
PNH granulocytes were measured as described in “Materials and methods.” The cut-off limit for the diagnosis of PNH clone was 1%.